Shopping Cart
- Remove All
- Your shopping cart is currently empty
Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $490 | In Stock | |
5 mg | $1,070 | In Stock | |
10 mg | $1,300 | In Stock | |
25 mg | $1,715 | In Stock | |
50 mg | $2,180 | In Stock | |
100 mg | $2,800 | In Stock |
Description | Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization. |
In vivo | In the alkali burn model, Befetupitant, a highly selective NK1R antagonist, was tested. Hemangiogenesis and lymphangiogenesis were effectively reduced (P<0.05) after topical application of Befetupitant for 4 days at both concentrations (0.4 and 1.6 mg/mL). However, both Befetupitant and its vehicle DMSO induced corneal opacity even in healthy controls, as observed during slit-lamp examination. Furthermore, fluorescein and hematoxylin-eosin staining confirmed DMSO toxicity by revealing epithelial damage and inflammatory cellular infiltration in the stroma. Despite Befetupitant's effectiveness in reducing corneal neovascularization (CNV) in the alkali burn model, its toxicity due to the DMSO vehicle led to the decision not to test it in the suture model[1]. |
Alias | Ro67-5930 |
Molecular Weight | 565.55 |
Formula | C29H29F6N3O2 |
Cas No. | 290296-68-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 6.88 mg/mL (12.16 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.